SPOTLIGHT: Big Pharma spurns Biogen Idec


Big Pharma just wasn't big enough to swallow Biogen Idec. A slew of drug makers kicked tires at the biotech company, but eventually concluded that the price was too high; after getting no definitive offers, Biogen took itself off the market. Release

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.